Previous close | 25.58 |
Open | 26.68 |
Bid | 26.34 x 300 |
Ask | 26.48 x 200 |
Day's range | 26.08 - 27.34 |
52-week range | 4.82 - 27.66 |
Volume | |
Avg. volume | 1,151,216 |
Market cap | 2.529B |
Beta (5Y monthly) | 0.77 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.91 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 46.71 |
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,500 shares of its common stock and 18,750 restricted stock units ("RSUs") to three (3) new non-executive employees under the Avidity Biosci
President and CEO Sarah Boyce of Avidity Biosciences Inc (NASDAQ:RNA) sold 28,000 shares of the company on April 2, 2024, according to a recent SEC filing.
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: